Fucosylated haptoglobin is a novel predictive marker of hepatocellular carcinoma after hepatitis C virus elimination in patients with advanced liver fibrosis
Patients with advanced fibrosis are at risk for developing hepatocellular carcinoma (HCC) even after hepatitis C virus (HCV) elimination. We previously reported that serum fucosylated haptoglobin (Fuc-Hp) levels increase as the disease progresses from chronic hepatitis to cirrhosis and then HCC. How...
Gespeichert in:
| Veröffentlicht in: | PloS one 2022-12, Vol.17 (12), p.e0279416 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 12 |
| container_start_page | e0279416 |
| container_title | PloS one |
| container_volume | 17 |
| creator | Shirai, Kumiko Hikita, Hayato Sakamori, Ryotaro Doi, Akira Tahata, Yuki Sakane, Sadatsugu Kamada, Yoshihiro Murai, Kazuhiro Nishio, Akira Yamada, Ryoko Kodama, Takahiro Nozaki, Yasutoshi Kakita, Naruyasu Ishida, Hisashi Nakanishi, Fumihiko Morishita, Naoki Imanaka, Kazuho Sakakibara, Mitsuru Tatsumi, Tomohide Miyoshi, Eiji Takehara, Tetsuo |
| description | Patients with advanced fibrosis are at risk for developing hepatocellular carcinoma (HCC) even after hepatitis C virus (HCV) elimination. We previously reported that serum fucosylated haptoglobin (Fuc-Hp) levels increase as the disease progresses from chronic hepatitis to cirrhosis and then HCC. However, it remains unclear whether serum Fuc-Hp levels can stratify the risk of HCC occurrence after a sustained virological response (SVR) is achieved with direct-acting antivirals (DAAs) in patients with advanced liver fibrosis.
Among 3,550 patients with chronic hepatitis C treated with DAAs at Osaka University Hospital and related hospitals, the stored sera of 140 patients who were diagnosed with F3 or F4 by liver biopsy before DAA treatment, achieved SVR, and had no history of HCC were available at both baseline and the end of treatment (EOT). We measured the Fuc-Hp levels in these samples.
The median serum levels of Fuc-Hp at EOT were significantly lower than those at baseline. During the 54.4-month follow-up period, 16 of 140 patients developed HCC. Multivariate Cox proportional hazards analysis revealed that high Fuc-Hp at EOT, high body mass index (BMI), and low albumin at EOT were independent risk factors for HCC occurrence. Patients with all three factors-high Fuc-Hp, high BMI, and low albumin-had a higher incidence of HCC than patients without these factors.
High serum Fuc-Hp levels at EOT were an independent risk factor for HCC occurrence after SVR. Combined with BMI and albumin, Fuc-Hp can stratify the risk of HCC occurrence among those with advanced fibrosis. |
| doi_str_mv | 10.1371/journal.pone.0279416 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2756654491</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A730815278</galeid><doaj_id>oai_doaj_org_article_0c188d920aa749eb89cf660080d4932f</doaj_id><sourcerecordid>A730815278</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-4cf3b5c1769774b5a71ea6d0c9117d67d64ea421163db2e27aac554656656ad43</originalsourceid><addsrcrecordid>eNqNk9-K1DAUxoso7rr6BqIBQfBixqRJk_ZGWAZXBxYW_HcbTtN0mjVtxiQd3YfxXc3sdJcpKEgDDef8zpfTrzlZ9pzgJaGCvL12ox_ALrdu0Euci4oR_iA7JRXNFzzH9OHR_iR7EsI1xgUtOX-cnVBesJxTepr9vhiVCzcWom5QB9voNtbVZkAmIECD22mLtl43RkWz06gH_1175FrU6S1Ep7S1owWPFHhlBtcDgjYm4jZtYlJZoZ3xY0Damt4MKeiS-ID2aT3EgH6a2CFodjCo1IJNp3jUmtq7YMLT7FELNuhn0_ss-3rx_svq4-Ly6sN6dX65ULzK44KpltaFIoJXQrC6AEE08AarihDR8LSYBpYTwmlT5zoXAKooGC94WtAwepa9POhurQtycjbIXOwJxiqSiPWBaBxcy603yYkb6cDI24DzGwk-GmW1xIqUZVPlGECwStdlpVrOMS5xw9IPaZPWu-m0se51o5INHuxMdJ4ZTCc3bifT12HK8iTwahLw7seoQ_xHyxO1gdSVGVqXxFRvgpLnguKSFLkoE7X8C5WeRvdGpbvVmhSfFbyZFSQm6l9xA2MIcv350_-zV9_m7OsjttNgYxecHfcXJsxBdgBVuiPB6_beOYLlfjTu3JD70ZDTaKSyF8eu3xfdzQL9A_dlDJw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2756654491</pqid></control><display><type>article</type><title>Fucosylated haptoglobin is a novel predictive marker of hepatocellular carcinoma after hepatitis C virus elimination in patients with advanced liver fibrosis</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><source>Public Library of Science (PLoS)</source><creator>Shirai, Kumiko ; Hikita, Hayato ; Sakamori, Ryotaro ; Doi, Akira ; Tahata, Yuki ; Sakane, Sadatsugu ; Kamada, Yoshihiro ; Murai, Kazuhiro ; Nishio, Akira ; Yamada, Ryoko ; Kodama, Takahiro ; Nozaki, Yasutoshi ; Kakita, Naruyasu ; Ishida, Hisashi ; Nakanishi, Fumihiko ; Morishita, Naoki ; Imanaka, Kazuho ; Sakakibara, Mitsuru ; Tatsumi, Tomohide ; Miyoshi, Eiji ; Takehara, Tetsuo</creator><creatorcontrib>Shirai, Kumiko ; Hikita, Hayato ; Sakamori, Ryotaro ; Doi, Akira ; Tahata, Yuki ; Sakane, Sadatsugu ; Kamada, Yoshihiro ; Murai, Kazuhiro ; Nishio, Akira ; Yamada, Ryoko ; Kodama, Takahiro ; Nozaki, Yasutoshi ; Kakita, Naruyasu ; Ishida, Hisashi ; Nakanishi, Fumihiko ; Morishita, Naoki ; Imanaka, Kazuho ; Sakakibara, Mitsuru ; Tatsumi, Tomohide ; Miyoshi, Eiji ; Takehara, Tetsuo</creatorcontrib><description>Patients with advanced fibrosis are at risk for developing hepatocellular carcinoma (HCC) even after hepatitis C virus (HCV) elimination. We previously reported that serum fucosylated haptoglobin (Fuc-Hp) levels increase as the disease progresses from chronic hepatitis to cirrhosis and then HCC. However, it remains unclear whether serum Fuc-Hp levels can stratify the risk of HCC occurrence after a sustained virological response (SVR) is achieved with direct-acting antivirals (DAAs) in patients with advanced liver fibrosis.
Among 3,550 patients with chronic hepatitis C treated with DAAs at Osaka University Hospital and related hospitals, the stored sera of 140 patients who were diagnosed with F3 or F4 by liver biopsy before DAA treatment, achieved SVR, and had no history of HCC were available at both baseline and the end of treatment (EOT). We measured the Fuc-Hp levels in these samples.
The median serum levels of Fuc-Hp at EOT were significantly lower than those at baseline. During the 54.4-month follow-up period, 16 of 140 patients developed HCC. Multivariate Cox proportional hazards analysis revealed that high Fuc-Hp at EOT, high body mass index (BMI), and low albumin at EOT were independent risk factors for HCC occurrence. Patients with all three factors-high Fuc-Hp, high BMI, and low albumin-had a higher incidence of HCC than patients without these factors.
High serum Fuc-Hp levels at EOT were an independent risk factor for HCC occurrence after SVR. Combined with BMI and albumin, Fuc-Hp can stratify the risk of HCC occurrence among those with advanced fibrosis.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0279416</identifier><identifier>PMID: 36542633</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Albumin ; Albumins ; Analysis ; Antibodies ; Antiviral agents ; Antiviral Agents - therapeutic use ; Biological markers ; Biology and Life Sciences ; Biopsy ; Body mass ; Body mass index ; Body size ; Carcinoma, Hepatocellular - pathology ; Care and treatment ; Cirrhosis ; Diagnosis ; Fibrosis ; Haptoglobin ; Haptoglobins - therapeutic use ; Health aspects ; Health services ; Hepacivirus ; Hepatitis ; Hepatitis C ; Hepatitis C virus ; Hepatitis C, Chronic - complications ; Hepatitis C, Chronic - drug therapy ; Hepatocellular carcinoma ; Hepatoma ; Humans ; Lectins ; Liver ; Liver cancer ; Liver cirrhosis ; Liver Cirrhosis - diagnosis ; Liver Neoplasms - pathology ; Magnetic resonance imaging ; Medicine and Health Sciences ; Patient outcomes ; Patients ; Risk analysis ; Risk factors ; Serum levels ; Statistical analysis ; Surveillance ; Sustained Virologic Response ; Ultrasonic imaging ; Viruses</subject><ispartof>PloS one, 2022-12, Vol.17 (12), p.e0279416</ispartof><rights>Copyright: © 2022 Shirai et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</rights><rights>COPYRIGHT 2022 Public Library of Science</rights><rights>2022 Shirai et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 Shirai et al 2022 Shirai et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-4cf3b5c1769774b5a71ea6d0c9117d67d64ea421163db2e27aac554656656ad43</citedby><cites>FETCH-LOGICAL-c692t-4cf3b5c1769774b5a71ea6d0c9117d67d64ea421163db2e27aac554656656ad43</cites><orcidid>0000-0001-5036-3457 ; 0000-0001-5485-902X ; 0000-0001-8634-2922 ; 0000-0002-9430-2362 ; 0000-0002-1580-607X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9770342/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9770342/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79342,79343</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36542633$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shirai, Kumiko</creatorcontrib><creatorcontrib>Hikita, Hayato</creatorcontrib><creatorcontrib>Sakamori, Ryotaro</creatorcontrib><creatorcontrib>Doi, Akira</creatorcontrib><creatorcontrib>Tahata, Yuki</creatorcontrib><creatorcontrib>Sakane, Sadatsugu</creatorcontrib><creatorcontrib>Kamada, Yoshihiro</creatorcontrib><creatorcontrib>Murai, Kazuhiro</creatorcontrib><creatorcontrib>Nishio, Akira</creatorcontrib><creatorcontrib>Yamada, Ryoko</creatorcontrib><creatorcontrib>Kodama, Takahiro</creatorcontrib><creatorcontrib>Nozaki, Yasutoshi</creatorcontrib><creatorcontrib>Kakita, Naruyasu</creatorcontrib><creatorcontrib>Ishida, Hisashi</creatorcontrib><creatorcontrib>Nakanishi, Fumihiko</creatorcontrib><creatorcontrib>Morishita, Naoki</creatorcontrib><creatorcontrib>Imanaka, Kazuho</creatorcontrib><creatorcontrib>Sakakibara, Mitsuru</creatorcontrib><creatorcontrib>Tatsumi, Tomohide</creatorcontrib><creatorcontrib>Miyoshi, Eiji</creatorcontrib><creatorcontrib>Takehara, Tetsuo</creatorcontrib><title>Fucosylated haptoglobin is a novel predictive marker of hepatocellular carcinoma after hepatitis C virus elimination in patients with advanced liver fibrosis</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Patients with advanced fibrosis are at risk for developing hepatocellular carcinoma (HCC) even after hepatitis C virus (HCV) elimination. We previously reported that serum fucosylated haptoglobin (Fuc-Hp) levels increase as the disease progresses from chronic hepatitis to cirrhosis and then HCC. However, it remains unclear whether serum Fuc-Hp levels can stratify the risk of HCC occurrence after a sustained virological response (SVR) is achieved with direct-acting antivirals (DAAs) in patients with advanced liver fibrosis.
Among 3,550 patients with chronic hepatitis C treated with DAAs at Osaka University Hospital and related hospitals, the stored sera of 140 patients who were diagnosed with F3 or F4 by liver biopsy before DAA treatment, achieved SVR, and had no history of HCC were available at both baseline and the end of treatment (EOT). We measured the Fuc-Hp levels in these samples.
The median serum levels of Fuc-Hp at EOT were significantly lower than those at baseline. During the 54.4-month follow-up period, 16 of 140 patients developed HCC. Multivariate Cox proportional hazards analysis revealed that high Fuc-Hp at EOT, high body mass index (BMI), and low albumin at EOT were independent risk factors for HCC occurrence. Patients with all three factors-high Fuc-Hp, high BMI, and low albumin-had a higher incidence of HCC than patients without these factors.
High serum Fuc-Hp levels at EOT were an independent risk factor for HCC occurrence after SVR. Combined with BMI and albumin, Fuc-Hp can stratify the risk of HCC occurrence among those with advanced fibrosis.</description><subject>Albumin</subject><subject>Albumins</subject><subject>Analysis</subject><subject>Antibodies</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Biological markers</subject><subject>Biology and Life Sciences</subject><subject>Biopsy</subject><subject>Body mass</subject><subject>Body mass index</subject><subject>Body size</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Care and treatment</subject><subject>Cirrhosis</subject><subject>Diagnosis</subject><subject>Fibrosis</subject><subject>Haptoglobin</subject><subject>Haptoglobins - therapeutic use</subject><subject>Health aspects</subject><subject>Health services</subject><subject>Hepacivirus</subject><subject>Hepatitis</subject><subject>Hepatitis C</subject><subject>Hepatitis C virus</subject><subject>Hepatitis C, Chronic - complications</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatocellular carcinoma</subject><subject>Hepatoma</subject><subject>Humans</subject><subject>Lectins</subject><subject>Liver</subject><subject>Liver cancer</subject><subject>Liver cirrhosis</subject><subject>Liver Cirrhosis - diagnosis</subject><subject>Liver Neoplasms - pathology</subject><subject>Magnetic resonance imaging</subject><subject>Medicine and Health Sciences</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Risk analysis</subject><subject>Risk factors</subject><subject>Serum levels</subject><subject>Statistical analysis</subject><subject>Surveillance</subject><subject>Sustained Virologic Response</subject><subject>Ultrasonic imaging</subject><subject>Viruses</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNqNk9-K1DAUxoso7rr6BqIBQfBixqRJk_ZGWAZXBxYW_HcbTtN0mjVtxiQd3YfxXc3sdJcpKEgDDef8zpfTrzlZ9pzgJaGCvL12ox_ALrdu0Euci4oR_iA7JRXNFzzH9OHR_iR7EsI1xgUtOX-cnVBesJxTepr9vhiVCzcWom5QB9voNtbVZkAmIECD22mLtl43RkWz06gH_1175FrU6S1Ep7S1owWPFHhlBtcDgjYm4jZtYlJZoZ3xY0Damt4MKeiS-ID2aT3EgH6a2CFodjCo1IJNp3jUmtq7YMLT7FELNuhn0_ss-3rx_svq4-Ly6sN6dX65ULzK44KpltaFIoJXQrC6AEE08AarihDR8LSYBpYTwmlT5zoXAKooGC94WtAwepa9POhurQtycjbIXOwJxiqSiPWBaBxcy603yYkb6cDI24DzGwk-GmW1xIqUZVPlGECwStdlpVrOMS5xw9IPaZPWu-m0se51o5INHuxMdJ4ZTCc3bifT12HK8iTwahLw7seoQ_xHyxO1gdSVGVqXxFRvgpLnguKSFLkoE7X8C5WeRvdGpbvVmhSfFbyZFSQm6l9xA2MIcv350_-zV9_m7OsjttNgYxecHfcXJsxBdgBVuiPB6_beOYLlfjTu3JD70ZDTaKSyF8eu3xfdzQL9A_dlDJw</recordid><startdate>20221221</startdate><enddate>20221221</enddate><creator>Shirai, Kumiko</creator><creator>Hikita, Hayato</creator><creator>Sakamori, Ryotaro</creator><creator>Doi, Akira</creator><creator>Tahata, Yuki</creator><creator>Sakane, Sadatsugu</creator><creator>Kamada, Yoshihiro</creator><creator>Murai, Kazuhiro</creator><creator>Nishio, Akira</creator><creator>Yamada, Ryoko</creator><creator>Kodama, Takahiro</creator><creator>Nozaki, Yasutoshi</creator><creator>Kakita, Naruyasu</creator><creator>Ishida, Hisashi</creator><creator>Nakanishi, Fumihiko</creator><creator>Morishita, Naoki</creator><creator>Imanaka, Kazuho</creator><creator>Sakakibara, Mitsuru</creator><creator>Tatsumi, Tomohide</creator><creator>Miyoshi, Eiji</creator><creator>Takehara, Tetsuo</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-5036-3457</orcidid><orcidid>https://orcid.org/0000-0001-5485-902X</orcidid><orcidid>https://orcid.org/0000-0001-8634-2922</orcidid><orcidid>https://orcid.org/0000-0002-9430-2362</orcidid><orcidid>https://orcid.org/0000-0002-1580-607X</orcidid></search><sort><creationdate>20221221</creationdate><title>Fucosylated haptoglobin is a novel predictive marker of hepatocellular carcinoma after hepatitis C virus elimination in patients with advanced liver fibrosis</title><author>Shirai, Kumiko ; Hikita, Hayato ; Sakamori, Ryotaro ; Doi, Akira ; Tahata, Yuki ; Sakane, Sadatsugu ; Kamada, Yoshihiro ; Murai, Kazuhiro ; Nishio, Akira ; Yamada, Ryoko ; Kodama, Takahiro ; Nozaki, Yasutoshi ; Kakita, Naruyasu ; Ishida, Hisashi ; Nakanishi, Fumihiko ; Morishita, Naoki ; Imanaka, Kazuho ; Sakakibara, Mitsuru ; Tatsumi, Tomohide ; Miyoshi, Eiji ; Takehara, Tetsuo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-4cf3b5c1769774b5a71ea6d0c9117d67d64ea421163db2e27aac554656656ad43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Albumin</topic><topic>Albumins</topic><topic>Analysis</topic><topic>Antibodies</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Biological markers</topic><topic>Biology and Life Sciences</topic><topic>Biopsy</topic><topic>Body mass</topic><topic>Body mass index</topic><topic>Body size</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Care and treatment</topic><topic>Cirrhosis</topic><topic>Diagnosis</topic><topic>Fibrosis</topic><topic>Haptoglobin</topic><topic>Haptoglobins - therapeutic use</topic><topic>Health aspects</topic><topic>Health services</topic><topic>Hepacivirus</topic><topic>Hepatitis</topic><topic>Hepatitis C</topic><topic>Hepatitis C virus</topic><topic>Hepatitis C, Chronic - complications</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatocellular carcinoma</topic><topic>Hepatoma</topic><topic>Humans</topic><topic>Lectins</topic><topic>Liver</topic><topic>Liver cancer</topic><topic>Liver cirrhosis</topic><topic>Liver Cirrhosis - diagnosis</topic><topic>Liver Neoplasms - pathology</topic><topic>Magnetic resonance imaging</topic><topic>Medicine and Health Sciences</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Risk analysis</topic><topic>Risk factors</topic><topic>Serum levels</topic><topic>Statistical analysis</topic><topic>Surveillance</topic><topic>Sustained Virologic Response</topic><topic>Ultrasonic imaging</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shirai, Kumiko</creatorcontrib><creatorcontrib>Hikita, Hayato</creatorcontrib><creatorcontrib>Sakamori, Ryotaro</creatorcontrib><creatorcontrib>Doi, Akira</creatorcontrib><creatorcontrib>Tahata, Yuki</creatorcontrib><creatorcontrib>Sakane, Sadatsugu</creatorcontrib><creatorcontrib>Kamada, Yoshihiro</creatorcontrib><creatorcontrib>Murai, Kazuhiro</creatorcontrib><creatorcontrib>Nishio, Akira</creatorcontrib><creatorcontrib>Yamada, Ryoko</creatorcontrib><creatorcontrib>Kodama, Takahiro</creatorcontrib><creatorcontrib>Nozaki, Yasutoshi</creatorcontrib><creatorcontrib>Kakita, Naruyasu</creatorcontrib><creatorcontrib>Ishida, Hisashi</creatorcontrib><creatorcontrib>Nakanishi, Fumihiko</creatorcontrib><creatorcontrib>Morishita, Naoki</creatorcontrib><creatorcontrib>Imanaka, Kazuho</creatorcontrib><creatorcontrib>Sakakibara, Mitsuru</creatorcontrib><creatorcontrib>Tatsumi, Tomohide</creatorcontrib><creatorcontrib>Miyoshi, Eiji</creatorcontrib><creatorcontrib>Takehara, Tetsuo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shirai, Kumiko</au><au>Hikita, Hayato</au><au>Sakamori, Ryotaro</au><au>Doi, Akira</au><au>Tahata, Yuki</au><au>Sakane, Sadatsugu</au><au>Kamada, Yoshihiro</au><au>Murai, Kazuhiro</au><au>Nishio, Akira</au><au>Yamada, Ryoko</au><au>Kodama, Takahiro</au><au>Nozaki, Yasutoshi</au><au>Kakita, Naruyasu</au><au>Ishida, Hisashi</au><au>Nakanishi, Fumihiko</au><au>Morishita, Naoki</au><au>Imanaka, Kazuho</au><au>Sakakibara, Mitsuru</au><au>Tatsumi, Tomohide</au><au>Miyoshi, Eiji</au><au>Takehara, Tetsuo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fucosylated haptoglobin is a novel predictive marker of hepatocellular carcinoma after hepatitis C virus elimination in patients with advanced liver fibrosis</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2022-12-21</date><risdate>2022</risdate><volume>17</volume><issue>12</issue><spage>e0279416</spage><pages>e0279416-</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Patients with advanced fibrosis are at risk for developing hepatocellular carcinoma (HCC) even after hepatitis C virus (HCV) elimination. We previously reported that serum fucosylated haptoglobin (Fuc-Hp) levels increase as the disease progresses from chronic hepatitis to cirrhosis and then HCC. However, it remains unclear whether serum Fuc-Hp levels can stratify the risk of HCC occurrence after a sustained virological response (SVR) is achieved with direct-acting antivirals (DAAs) in patients with advanced liver fibrosis.
Among 3,550 patients with chronic hepatitis C treated with DAAs at Osaka University Hospital and related hospitals, the stored sera of 140 patients who were diagnosed with F3 or F4 by liver biopsy before DAA treatment, achieved SVR, and had no history of HCC were available at both baseline and the end of treatment (EOT). We measured the Fuc-Hp levels in these samples.
The median serum levels of Fuc-Hp at EOT were significantly lower than those at baseline. During the 54.4-month follow-up period, 16 of 140 patients developed HCC. Multivariate Cox proportional hazards analysis revealed that high Fuc-Hp at EOT, high body mass index (BMI), and low albumin at EOT were independent risk factors for HCC occurrence. Patients with all three factors-high Fuc-Hp, high BMI, and low albumin-had a higher incidence of HCC than patients without these factors.
High serum Fuc-Hp levels at EOT were an independent risk factor for HCC occurrence after SVR. Combined with BMI and albumin, Fuc-Hp can stratify the risk of HCC occurrence among those with advanced fibrosis.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>36542633</pmid><doi>10.1371/journal.pone.0279416</doi><tpages>e0279416</tpages><orcidid>https://orcid.org/0000-0001-5036-3457</orcidid><orcidid>https://orcid.org/0000-0001-5485-902X</orcidid><orcidid>https://orcid.org/0000-0001-8634-2922</orcidid><orcidid>https://orcid.org/0000-0002-9430-2362</orcidid><orcidid>https://orcid.org/0000-0002-1580-607X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2022-12, Vol.17 (12), p.e0279416 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2756654491 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free Full-Text Journals in Chemistry; Public Library of Science (PLoS) |
| subjects | Albumin Albumins Analysis Antibodies Antiviral agents Antiviral Agents - therapeutic use Biological markers Biology and Life Sciences Biopsy Body mass Body mass index Body size Carcinoma, Hepatocellular - pathology Care and treatment Cirrhosis Diagnosis Fibrosis Haptoglobin Haptoglobins - therapeutic use Health aspects Health services Hepacivirus Hepatitis Hepatitis C Hepatitis C virus Hepatitis C, Chronic - complications Hepatitis C, Chronic - drug therapy Hepatocellular carcinoma Hepatoma Humans Lectins Liver Liver cancer Liver cirrhosis Liver Cirrhosis - diagnosis Liver Neoplasms - pathology Magnetic resonance imaging Medicine and Health Sciences Patient outcomes Patients Risk analysis Risk factors Serum levels Statistical analysis Surveillance Sustained Virologic Response Ultrasonic imaging Viruses |
| title | Fucosylated haptoglobin is a novel predictive marker of hepatocellular carcinoma after hepatitis C virus elimination in patients with advanced liver fibrosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T00%3A48%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fucosylated%20haptoglobin%20is%20a%20novel%20predictive%20marker%20of%20hepatocellular%20carcinoma%20after%20hepatitis%20C%20virus%20elimination%20in%20patients%20with%20advanced%20liver%20fibrosis&rft.jtitle=PloS%20one&rft.au=Shirai,%20Kumiko&rft.date=2022-12-21&rft.volume=17&rft.issue=12&rft.spage=e0279416&rft.pages=e0279416-&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0279416&rft_dat=%3Cgale_plos_%3EA730815278%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2756654491&rft_id=info:pmid/36542633&rft_galeid=A730815278&rft_doaj_id=oai_doaj_org_article_0c188d920aa749eb89cf660080d4932f&rfr_iscdi=true |